Nobivac Ducat vet.
Active substance
ATC code
Species
Cats.
Indications
Active immunisation of cats to reduce the clinical signs caused by infection with feline rhinotracheitis virus (FVR) and feline calicivirus (FCV) infections.
Onset of immunity: 4 weeks.
Duration of immunity: 1 year.
Dose to be administered and administration route
Allow the sterile solvent provided to reach room temperature. Aseptically reconstitute the lyophilised vaccine with one ml of the solvent. Shake well after addition of the solvent. One ml of the reconstituted vaccine should be given by subcutaneous injection.
Visual appearance of the reconstituted product: off-pink or pink coloured suspension.
Vaccination schedule:
Primary vaccination:
Cats from 8 weeks of age onwards should receive two vaccinations with an interval of 3 – 4 weeks.
Revaccination:
Annual booster
During the initial vaccination course, the vaccine in the Nobivac range containing rabies antigen, strain Pasteur RIV, may be used to reconstitute the vaccine at the vaccination at 12 weeks of age (where this product and the combined use is authorised).
Adverse reactions
Cats:
|
Very common (> 1 animal / 10 animals treated): |
Injection site swelling.1 |
|
Common (1 to 10 animals / 100 animals treated): |
Elevated temperature.2 |
|
Rare (1 to 10 animals / 10,000 animals treated): |
Hypersensitivity reactions (e.g. pruritus, dyspnoea, vomiting, diarrhoea and collapse including anaphylaxis).3 Lethargy.4 |
|
Very rare (< 1 animal /10,000 animals treated, including isolated reports): |
Injection site pain.1 Febrile limping syndrome reactions in kittens.5 |
1 A local swelling (≤ 5 mm), sometimes painful, may be observed at the injection site for one day post-vaccination.
2 Elevated body temperature (up to 40 °C) may occur for 1 – 2 days post vaccination.
3 Sometimes fatal. If such a reaction occurs, appropriate treatment should be administered without delay.
4 Lethargy may be observed during the first day after vaccination.
5 As reported in the literature, febrile limping syndrome reactions in kittens may occur after the use of any vaccine containing a feline calicivirus component.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See section ‘Contact details’ of the package leaflet.
